

Resource Summary Report

Generated by [RRID](#) on Aug 5, 2026

Anti-TAK1, phospho (Thr184 / Thr187) Antibody, Unconjugated

RRID:AB_390772

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4531, RRID:AB_390772

Antibody Information

URL: http://antibodyregistry.org/AB_390772

Proper Citation: Cell Signaling Technology Cat# 4531, RRID:AB_390772

Target Antigen: TAK1, phospho (Thr184 / Thr187)

Clonality: unknown

Comments: Applications: W

Antibody Name: Anti-TAK1, phospho (Thr184 / Thr187) Antibody, Unconjugated

Description: This unknown targets TAK1, phospho (Thr184 / Thr187)

Target Organism: human

Antibody ID: AB_390772

Vendor: Cell Signaling Technology

Catalog Number: 4531

Record Creation Time: 20250820T021158+0000

Record Last Update: 20250820T125739+0000

Ratings and Alerts

No rating or validation information has been found for Anti-TAK1, phospho (Thr184 / Thr187) Antibody, Unconjugated.

No alerts have been found for Anti-TAK1, phospho (Thr184 / Thr187) Antibody, Unconjugated.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen IT, et al. (2021) Promyelocytic leukemia protein targets MK2 to promote cytotoxicity. EMBO reports, 22(12), e52254.

Wang L, et al. (2021) Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. Cell metabolism, 33(7), 1372.

Liu D, et al. (2020) TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. Cell metabolism, 31(4), 726.

Da Ros F, et al. (2017) Targeting Interleukin-1? Protects from Aortic Aneurysms Induced by Disrupted Transforming Growth Factor ? Signaling. Immunity, 47(5), 959.